Drug concentrations were selected to halt cell cycle progression without affecting cell viability: 94T778 10 M, A375, SKMEL28 and AU565 4 M, SKBR3 0.8 M. The pharmacologic inhibition of MTOR repressed expression of the homologous recombination (HR) and Fanconi Anemia (FA) pathways, and selectively high-fidelity but not error-prone DNA polymerases  in all cancer cell lines sequenced SOURCE: David Goode (david.goode@petermac.org) - Evolutionary Cancer Genomics Peter MacCallum Cancer Centre

GSE148344: EXP. 229_AC_RNAseq data of human cancer cell lines 94T778, SKBR3, AU565, SKMEL28 and A375 exposed to the selective MTOR inhibitor torkinib (PP242, Selleckchem, TX, USA) for 72 hours.

Pluto Bioinformatics

GSE148344: EXP. 229_AC_RNAseq data of human cancer cell lines 94T778, SKBR3, AU565, SKMEL28 and A375 exposed to the selective MTOR inhibitor torkinib (PP242, Selleckchem, TX, USA) for 72 hours.